Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

News

News Brexit – what is the current status (on research)?

Brexit – what is the current status (on research)?

The primary principle of the EU27 remains that before talks on the future can begin, the negotiations on an orderly withdrawal must first make enough progress to prove that the UK is a credible negotiating partner. An orderly exit procedure for the EU concerns mainly the questions of financial settlement, citizens’ rights and the situation of Northern Ireland.

News Avicenna Alliance at BMES Conference in Washington- video available!

Avicenna Alliance at BMES Conference in Washington- video available!

In the week of 15-18 May 2017 the Avicenna Alliance was in Washington DC, following an invitation by the FDA and by the staff of Senator T. Cochran to discuss the role of in silico medicine. The Delegation consisted of Avicenna Alliance Members, an EMA Representative, FDA Representatives, US-Avicenna Contacts, US Senate Staff and the RPP Group.

News FDA confirms its investment in modeling and simulation for improving drug development

FDA confirms its investment in modeling and simulation for improving drug development

Scott Gottlieb commissioner of the USA Food & Drug Administration has recently written an article for the FDA Blog “FDA Voice” on the impact of the 21st Century Cures Act, which authorised $6.3 billion in additional funding, part of which is dedicated to research and drug development.

News MEP Grossetête to visit NovaDiscovery site

MEP Grossetête to visit NovaDiscovery site

On 7 July 2017 MEP Françoise Grossetête (EPP, France) will visit the new site of Avicenna Member, NovaDiscovery in Lyon.

News Boston Scientific joins Avicenna Alliance

Boston Scientific joins Avicenna Alliance

As further evidence of the Alliance’s growing momentum, Avicenna Alliance is happy to announce the newest addition to its list of members: Boston Scientific.

News Meetings at US Senate Buildings

Meetings at US Senate Buildings

In the week of 15-18 May 2017 the Avicenna Alliance was in Washington DC, following an invitation by the FDA and by the staff of Senator T. Cochran to discuss the role of in silico medicine. The Delegation consisted of Avicenna Alliance Members, an EMA Representative, FDA Representatives, US-Avicenna Contacts, US Senate Staff and the RPP Group.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2024 Avicenna Alliance | powered by We Berry